Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$209.18
-0.8%		$196.37
$39.17
▼
$224.31
$44.77B1.42.97 million shs526,852 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.78%-4.65%+9.00%+41.31%+430.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$209.18
-0.8%		$196.37
$39.17
▼
$224.31
$44.77B1.42.97 million shs526,852 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.78%-4.65%+9.00%+41.31%+430.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.95
Moderate Buy$200.74-3.97% Downside

Current Analyst Ratings Breakdown

Latest RVMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$240.00 ➝ $275.00
8/28/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$220.00 ➝ $265.00
8/28/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$240.00 ➝ $275.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$203.00 ➝ $251.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$248.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$230.00 ➝ $260.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$320.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$195.00 ➝ $280.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$201.00 ➝ $225.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$231.00 ➝ $239.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,869.23N/AN/A$12.16 per share17.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
 |  zacks.comhttps://www.zacks.com/stock/news/2985294/revolution-medicines-rvmd-up-6-6-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2985294
Revolution Medicines logo displayed over a laboratory background with a microscope, flasks, and test tubes.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
...
September 4 at 10:20 AM  |  marketbeat.comhttps://www.marketbeat.com/articles/revolution-medicines-got-its-breakthroughwhat-moves-it-next/
Lorence Kim Sells 56,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
September 4 at 4:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003491
Corient Private Wealth LP Acquires New Stake in Revolution Medicines, Inc. $RVMD
September 4 at 3:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-acquires-new-stake-in-revolution-medicines-inc-rvmd-2026-09-04/
J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)
September 3 at 10:44 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/4421915/jp-morgan-sticks-to-their-buy-rating-for-revolution-medicines-rvmd/
Revolution Medicines Highlights NEJM Publication Of RASONQUE Lung Cancer Data
September 3 at 7:43 AM  |  rttnews.comhttps://www.rttnews.com/3688083/revolution-medicines-highlights-nejm-publication-of-rasonque-lung-cancer-data.aspx
Revolution Medicines (NASDAQ:RVMD) Director Lorence Kim Sells 56,000 Shares
September 3 at 6:06 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rvmd-insider-buying-and-selling-2026-09-03/
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
September 2 at 5:50 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355564/0/en/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines-rasonque-daraxonrasib-in-metastatic-non-small-cell-lung-cancer.html
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $11,381,440.00 in Stock
September 2 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-revolution-medicines-nasdaq-rvmd-director-sells-1138144000-in-stock-2026-09-02/
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Revolution Medicines (RVMD)
September 2 at 10:17 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/4401327/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-revolution-medicines-rvmd/
Revolution Medicines, Inc. $RVMD Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
September 2 at 5:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-acquired-by-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-2026-09-02/
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Needham & Company LLC Analyst Says
September 2 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997636
Revolution Medicines: Benefit Vs. Reality Compared To Peer Therapeutics
September 1 at 10:39 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4942111-revolution-medicines-benefit-vs-reality-compared-to-peer-therapeutics
Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $275.00
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-needham-company-llc-raises-revolution-medicines-nasdaq-rvmd-price-target-to-27500-2026-08-31/
Moore Capital Management LP Has $15.30 Million Holdings in Revolution Medicines, Inc. $RVMD
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moore-capital-management-lp-has-1530-million-holdings-in-revolution-medicines-inc-rvmd-2026-08-31/
Public Employees Retirement System of Ohio Buys Shares of 77,402 Revolution Medicines, Inc. $RVMD
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-buys-shares-of-77402-revolution-medicines-inc-rvmd-2026-08-31/
HC Wainwright Issues Pessimistic Outlook for RVMD Earnings
August 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30993285
HC Wainwright Has Pessimistic Outlook of RVMD Q3 Earnings
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-pessimistic-outlook-of-rvmd-q3-earnings-2026-08-31/
Patients with the deadliest cancer finally have something that works
August 30, 2026  |  malaysia.news.yahoo.comhttps://malaysia.news.yahoo.com/patients-deadliest-cancer-finally-something-170700573.html
Revolution Medicines, Inc. $RVMD Shares Sold by Jasper Ridge Partners L.P.
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-sold-by-jasper-ridge-partners-lp-2026-08-30/
Revolution Medicines, Inc. $RVMD Shares Sold by Wellington Management Group LLP
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-sold-by-wellington-management-group-llp-2026-08-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Revolution Medicines logo displayed over a laboratory background with a microscope, flasks, and test tubes.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
By Chris Markoch | September 4, 2026
Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$210.00 -0.87 (-0.41%)
As of 03:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas